The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Interferons: a promising potential therapy for MPN
Ruben Mesa, MD, FACP, from the Mayo Cancer Clinic Center, Rochester, MN, USA, provides us an insight into the potential of treating patients with myeloproliferative neoplasms (MPN) with interferons. Here, he discusses the PROUD-PV study (NCT01949805), a Phase III trial comparing the efficacy and safety of the novel interferon AOP2014 against hydroxyurea in treating polycythemia vera, and notes that there may be selectivity in the interferon for clones of MPN. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
